King Pharmaceuticals may be all fired up about the possibility of bringing Alpharma into its specialty-drug fold, but the feeling isn't mutual. And Alpharma isn't just saying no. It's working to hold King off. The company has adopted a shareholder rights plan designed to guard against a King takeover. If anyone acquires 15 percent or more of Alpharma's common stock--or launches a tender offer (hint, hint)--the rights will become exercisable.
But the plan isn't designed to head off every acquisition offer, CEO Dean Mitchell said in a statement. Just those whose terms aren't fair and "in the best interests of all Alpharma shareholders."
As you know, King offered $33 a share, or some $1.4 billion for Alpharma, but the company rebuffed that offer. King then went public with its bid in hopes of persuading Alpharma management, saying it was open to negotiation and preferred a friendly takeover. But Alpharma wasn't convinced.
So King filed with the FTC last week, saying it intends to buy a majority share in Alpharma. That's a clear signal of King's intent to pursue a tender offer anyway. Alpharma investors seem sure that King will come back with a higher offer; the stock closed at $37.50 on Friday.
- see Alpharma's release
Alpharma shares skyrocket on King's buyout offer
King offers $1.4B for Alpharma
Alpharma touts Phase III pain drug data
Alpharma sub inks $202M deal for pain drug
Alpharma to proceed with painkiller trial
Investors bid up Alpharma stock on rumors of a sale